Financials data is unavailable for this security.
View more
Year on year Bristol-Myers Squibb Co grew net income 26.84% 6.33bn to 8.03bn despite relatively flat revenue growth.
Gross margin | 76.18% |
---|---|
Net profit margin | -14.04% |
Operating margin | -11.94% |
Return on assets | -6.94% |
---|---|
Return on equity | -26.70% |
Return on investment | -9.03% |
More ▼
Cash flow in USDView more
In 2023, Bristol-Myers Squibb Co increased its cash reserves by 23.53%, or 2.19bn. The company earned 13.86bn from its operations for a Cash Flow Margin of 30.80%. In addition the company used 2.30bn on investing activities and also paid 9.42bn in financing cash flows.
Cash flow per share | 1.72 |
---|---|
Price/Cash flow per share | 28.40 |
Book value per share | 8.39 |
---|---|
Tangible book value per share | -16.85 |
More ▼
Balance sheet in USDView more
Current ratio | 1.16 |
---|---|
Quick ratio | 1.02 |
Total debt/total equity | 3.08 |
---|---|
Total debt/total capital | 0.7543 |
More ▼
Growth rates in USD
SmartText is unavailable
Div yield(5 year avg) | 3.21% |
---|---|
Div growth rate (5 year) | 7.34% |
Payout ratio (TTM) | -- |
EPS growth(5 years) | 4.90 |
---|---|
EPS (TTM) vs TTM 1 year ago | -186.74 |
More ▼